Skip to main content
OpenTrials
Completed

NCT Number: NCT02298582

Safety of Intranasal Fentanyl (PecFent®) in the Treatment of Procedural Pain in the Elderly

The purpose of this study is to evaluate the safety of the intranasal fentanyl in pain induced by wound care and rehabilitation in the elderly. The project would also provide a preliminary assessment of the effectiveness of intranasal fentanyl used in procedural pains.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pain Due to Certain Specified Procedures Neurologic Manifestations Pain Pain, Procedural Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

76 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

University hospital of Grenoble

Grenoble, Isere, 38043, France

About this study

This is a safety clinical trial. This trial is monocentric, open label, non-randomized.

Sixty elderly patients will be enrolled in this study, 30 with bedsore cares and 30 with rehabilitation sessions.

Six bedsore cares or rehabilitation sessions will be assessed for each subject. For each session, patient pain will be evaluated using a visual analogic scale VAS at different times, before session, 5 minutes then 20 minutes after the beginning of the session, and a last VAS 1 hour after the end of the session. During the two first sessions, patients do not receive Pecfent® to assess their basal pain. During the following four sessions, patients will receive transmucosal fentanyl, 10 minutes before care.

An evaluation of respiratory rate and of the level of sedation will occur at different time : after 5 minutes then 20 minutes of care, at the end of the care session,at half an hour then one hour after the care session.

At the end of sessions,

  • The nurse or physiotherapist will assess their satisfaction regarding the objectives achieved during the session with a four points verbal descriptor scale (very satisfied, satisfied, not much satisfied, not satisfied). They will also evaluate at the end of the four last session their satisfaction regarding the convenience of the use of pecfent® and its contribution towards care.
  • Patients will assess their satisfaction regarding the course of the session with a verbal descriptor scale (VDS) and their level of anxiety felt during the session with a VAS.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hospitalized geriatric patient requiring care or rehabilitation
  • Patient with pain during treatment or mobilization. (VAS ≥ 4)
  • Written Informed consent

Exclusion criteria

  • All unstable fractures
  • Confusion: unable to assess their level of pain using a VAS.
  • Contraindications to PecFent ® (. Hypersensitivity to the active substance or to any of the excipients listed in section Composition Use in patients who had never received treatment for opioid severe respiratory depression or severe obstructive pulmonary disease.)
  • Person under legal protection

Treatment and study plan

Intranasal Fentanyl

Drug

During the two first sessions of care or rehabilitation, patients do not receive Pecfent® in order to assess their basal pain. During the following four sessions, patients will receive transmucosal fentanyl, 10 minutes before care. A titration of PecFent will be done at each session

Primary outcomes

  1. Safety of intranasal fentanyl as measured by the nature and frequency of adverse effects.

    Time frame: 5 days after the last intake of fentanyl.

    The nature and frequency of adverse effects will be described. The collection of adverse events will be first, with the collection of spontaneous patient complaints from nurses on the other hand, by systematic screening with the patient. Monitoring of respiratory rate and level of sedation will also be set up.

Secondary outcomes

  1. Effectiveness of intranasal fentanyl in procedural pain using a VAS (Visual Analogic Scale) of pain.

    Time frame: Evolution of the level of pain (VAS) since the beginning of care until one hour after the end of session (on average at 2 hours).

    VAS will be evaluated during each session at t0, t0+15min, t0+30min, and 1hour after the session (on average at 2 hours)

  2. Fentanyl impact on the goals of care as measured by a caregiver satisfaction scale.

    Time frame: At the end of session of care or rehabilitation (on average at 1 hour).

    At the end of each session of care or rehabilitation, it will be proposed to the caregiver, a scale measuring its satisfaction regarding the objectives achieved during the session.

  3. Nurse or physiotherapist satisfaction regarding use of PecFent® as measured by a verbal descriptor scale

    Time frame: 1 hour after the last intake of fentanyl

    Nurse or physiotherapist evaluation satisfaction regarding the convenience of the use of pecfent® and its contribution towards care using a verbal descriptor scale

  4. Impact of PecFent® on patient feelings during care or rehabilitation sessions as measured by a verbal descriptor scale

    Time frame: At the end of Session of care or rehabilitation (on average at 1 hour).

    Patient evaluation at the end of sessions:

    • Patient satisfaction regarding the course of the session with a VDS

Sponsors and collaborators

Lead sponsor

University Hospital, Grenoble

Other

Registry information

Official study title

Safety of Intranasal Fentanyl (PecFent®) in the Treatment of Procedural Pain in the Elderly With or Without Background Treatment.

Acronym: FENTA

Important dates

Study start
2014
Primary completion
2017
Study completion
2018
First posted
Nov 24, 2014
Registry last updated
May 8, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.